Immuneel Therapeutics (Immuneel) has entered into a collaboration and licensing agreement with Hospital Clinic de Barcelona (HCB) and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) for treatment of B cell malignancies.

The collaboration opens up opportunities for co-development of advanced assets to be deployed in Spain and India, Immuneel acquired the exclusive rights to develop and commercialise autologous ARI-0001 – a CD19 Chimeric antigen receptor (CAR) T cell therapy, in India.

This agreement puts Immuneel in the pursuit of offering accessible and affordable CAR Ts to patients in India through registration clinical trials and its investments in further process optimisation.

Kiran Mazumdar Shaw, Co-founder, Immuneel, said, “This partnership with HCB & IDIBAPS is pathbreaking and heralds the advent of life saving CAR T therapy for patients in India. Immuneel is committed to providing affordable access to this therapy at facilities housed at the Mazumdar Shaw Cancer Centre. I would

Read More



a clear blue sky: Aboitiz to venture into small cell business


© STAR/File
Aboitiz to venture into small cell business

MANILA, Philippines — Aboitiz InfraCapital Inc. is venturing into the small cell network business to supplement its common tower venture.

The infrastructure arm of the Aboitiz Group said it is ready to deploy small cell networks in key cities to boost connectivity.

The company is offering its small cell network nationwide to support telecommunication companies and internet service providers (ISPs) with its wireless network capacity and coverage.

“Consistent with our commitment to helping meet the demand for better telecommunication services, we are happy to partner with telcos and other ISPs in accelerating the expansion of their network capacity and coverage throughout the country,” Aboitiz InfraCapital’s small cell business general manager Rafael Aboitiz said.

A small cell network is a series of small low-powered, short-ranged antennas that provide coverage and capacity, meant to work in conjunction with macro cell towers.

Aboitiz InfraCapital

Read More

The Centre has received requests from companies for setting up 20 gigaatts (GW) of domestic solar module and cell manufacturing capacity.

Speaking at the India PV Edge 2020 virtual symposium, Minister of State (Independent Charge) for Power and New and Renewable Energy RK Singh said: “Expression of intent for setting up 20 GW of module and cell manufacturing have been received by the Centre.”

According to Singh, this is on the back of various steps taken by the government to support the domestic manufacturing industry, “These have come after India decided to have a safeguard duty, customs duty and the Approved List of Models and Manufacturers (ALMM) to prevent dumping and protect the domestic solar manufacturing industry.”

Singh said the ALMM is expected to be approved and finalised for new tenders from this month itself.

Commenting on how there may be more support for innovation in the solar energy sector,

Read More

For income investors seeking to initiate or add some tech stocks with attractive dividend yields, your time has come, asserts Bryan Perry, editor of Cash Machine.

The recent correction has provided a sweet entry point for buying into the 5G and cloud storage markets, where the best-of-breed stocks in both sub-sectors are trading 10-15% off their 52-week highs.

The advent of the remote working economy, artificial intelligence-driven platforms, big data enterprise networks, internet of Things (IoT), digital payments and mobile e-commerce are all huge contributors to cell tower and data center operators.

The global telecom tower market accounted for $40 billion in 2017 and is expected to grow at a compound annual growth rate (CAGR) of 18.0% during the forecast period 2018-2025, to reach $145 billion by 2025.

The two stocks within this space that rule the roost are American Tower REIT (AMT), paying a current dividend yield

Read More

VANCOUVER, BC, Sept. 21, 2020 /CNW/ – Ballard Power Systems (NASDAQ: BLDP) (TSX: BLDP) today noted that China’s government has announced a new official policy regarding Fuel Cell Electric Vehicles, or FCEVs, which is expected to support the adoption of FCEVs in selected demonstration regions in China.   

“With a target to achieve 1 million Fuel Cell Electric Vehicles on China’s roads by 2030, this new fuel cell policy sets a framework for the scaled adoption of FCEVs,” said Randy MacEwen, Ballard President and CEO. “We believe this new policy signifies the strategic importance China places on FCEVs both from a decarbonization perspective as well as a competitive industrial perspective. The new policy comes just as the Weichai-Ballard joint venture has been recently commissioned in Shandong Province with annual manufacturing capacity in excess of 1 Gigawatt of fuel cell stacks. We believe the Weichai-Ballard joint venture is well

Read More

BAC NINH, Vietnam, Sept. 15, 2020 /PRNewswire/ — Dehui is anchored by its self-owned, newly-constructed, fully automatic cell and module lines in Vietnam with new manufacturing equipment with 1.5GW annual capacity of 158.75mm, 166mm, 182mm, and 210mm 9 bus-bar solar cells and 2.25GW annual capacity of half-cut monofacial and bifacial Mono PERC module. The modules’ reported efficiency of 22.5% is the most advanced and efficient among Vietnamese makers.

Mass production of 166mm 9 bus-bar half-cut bifacial Mono PERC modules which is the first case in Vietnam has occupied Dehui latest 700MW module lines. Next year, mass production of 182mm 12 bus-bar modules will be main task to Dehui.

As ambitions to ramp up shipments, Dehui is also planning to majorly scale up production. Dehui currently runs 250,000 square feet split across five production lines but has set aside a further one million square feet, set to host factories in

Read More

DUBLIN–(Business Wire)–The “Primary Cells – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.

The publisher brings years of research experience to the 5th edition of this report. The 175-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Global Primary Cells Market to Reach US$1.3 Billion by the Year 2027

Amid the COVID-19 crisis, the global market for Primary Cells estimated at US$775.5 Million in the year 2020, is projected to reach a revised size of US$1.3 Billion by 2027, growing at a CAGR of 7.1% over the period 2020-2027.

Human Primary Cells, one of the segments analyzed in the report, is projected to grow at a 7.5% CAGR to reach US$1 Billion by the end of the analysis period. After an early analysis of the

Read More

(RTTNews) – Roche (RHHBY) said the United States Food and Drug Administration or FDA has approved Gavreto for the treatment of adults with metastatic rearranged during transfection or RET fusion-positive non-small cell lung cancer as detected by an FDA approved test.

The company noted that this indication was approved under the FDA’s Accelerated Approval programme, based on data from the phase I/II ARROW study. Continued approval for this indication might be contingent upon verification and description of clinical benefit in a confirmatory trial.

Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations. It is jointly commercialised by Genentech, a wholly owned member of the Roche Group, and Blueprint Medicines in the US and would be commercialised by Roche outside of the US, excluding Greater China.

Gavreto is now the sixth FDA-approved medicine in Roche’s portfolio of treatments for lung cancer, the company

Read More